Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Effective Platinum-Based Salvage Chemotherapy for Periportal Posttransplant Lymphoproliferative Disorder After an Orthotopic Liver Transplant.

about

Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Effective Platinum-Based Salvage Chemotherapy for Periportal Posttransplant Lymphoproliferative Disorder After an Orthotopic Liver Transplant.

Item

http://www.wikidata.org/entity/Q42193961

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@en

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@nl

type

Item

label

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@en

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@nl

prefLabel

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@en

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@nl

P1476

Rituximab, Dexamethasone, Cyta ...... n Orthotopic Liver Transplant.

@en

P2093

Bryan Whitson

http://www.w3.org/2001/XMLSchema#string

Latifa Sage Silski

http://www.w3.org/2001/XMLSchema#string

Mitchell Henry

http://www.w3.org/2001/XMLSchema#string

Shaylyn Bennett

http://www.w3.org/2001/XMLSchema#string

Sylvester Black

http://www.w3.org/2001/XMLSchema#string

P2860

Epstein-Barr virus infection and posttransplant lymphoproliferative disorder

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.

Lymphoproliferative disorders after liver transplantation.

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.

Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.

Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?

Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.

Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey.

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

P304

475-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6002/ECT.2014.0053

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eliza W Beal

P577

2014-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25184436

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5800743

http://www.w3.org/2001/XMLSchema#string